TSX:ONC 0.88 CAD +0.02 +1.73% Volume: 13,099 May 28, 2015
NASDAQ:ONCY 0.70 USD +0.01 +0.72% Volume: 454,631 May 28, 2015

A Novel Approach to Cancer Therapeutics

Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics’ clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.

Latest News

May 19, 2015 Oncolytics Biotech® Inc. Announces Phase 1 Study in Pediatric Patients with Brain Tumors
May 07, 2015 Oncolytics Biotech® Inc. Announces 2015 First Quarter Results
May 06, 2015 Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Gastric Cancer
Sign up to receive e-mail updates *